Read more in the study ‘The impact of Covid-19 on access to Parkinson’s disease medication’.
Has Covid-19 impacted access to Parkinson’s medication?
Author: Simge Eva DoganPublished: 17 September 2020
Prep: Cook: Serves:
New research has found that the coronavirus pandemic has affected access to medication for people living with Parkinson’s disease.
The sub-study used information from a survey conducted by the International Parkinson and Movement Disorder Society. The results from 346 participants showed that 22.8% of high-income and 88.9% of low-income countries’ respondents agreed that the coronavirus crisis had impacted people’s access to Parkinson’s medication. Some respondents reported increased disability, increased hospitalisation and increased mortality as factors. The majority of those who completed the survey were doctors.
The researchers concluded: “Our results offer preliminary data that the Covid-19 pandemic has affected Parkinson’s disease patients’ access to regular medication.
“Covid-19 has diverted resources away from chronic conditions towards the fight against Covid-19 in many countries. Resource-poor countries seem to be disproportionately affected compared to their affluent counterparts.”
For more information on Parkinson’s and Covid-19 please visit the EPDA website.
Share this story
How Parkinson’s genetics is transforming drug development
Find out about the latest research into Parkinson’s geneticsREAD MORE
Investigating rhythm, dance and Parkinson’s disease
Dr Psyche Loui tells us about “dance intervention”READ MORE
Three Parkinson’s books to watch out for in 2020
We handpick the most anticipated Parkinson’s reads this yearREAD MORE